Tissue-type plasminogen activator binds to Aβ and AIAPP amyloid fibrils with multiple domains

References

• Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005;93:655–60
   PubMedGoogle Scholar
• Benilova I, Karran E, Strooper BD. The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 2012;15:349–57
   PubMed Web of Science ®Google Scholar
• Kingston IB, Castro MJ, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat Med 1995;1:138–42
   PubMedGoogle Scholar
• Wnendt S, Wetzels I, Günzler WA. Amyloid β peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase. Thromb Res 1997;85:217–24
   PubMedGoogle Scholar
• Kranenburg O, Bouma B, Kroon-Batenburg LMJ, Reijerkerk A, Wu Y-P, Voest EE, Gebbink MFBG. Tissue-type plasminogen activator is a multiligand cross-β structure receptor. Curr Biol 2002;12:1833–9
   PubMed Web of Science ®Google Scholar
• Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid β-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 1999;38:11570–6
   PubMedGoogle Scholar
• Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, Walker D, et al. The plasmin system is induced by and degrades amyloid-β aggregates. J Neurosci 2000;20:3937–46
   PubMedGoogle Scholar
• Tucker HM, Kihiko-Ehmann M, Wright S, Rydel RE, Estus S. Tissue plasminogen activator requires plasminogen to modulate amyloid-β neurotoxicity and deposition. J Neurochem 2000;75:2172–7
   PubMedGoogle Scholar
• Lee J-Y, Kweon H-S, Cho E, Lee J-Y, Byun H-R, Kim DH, Kim Y-H, et al. Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer’s disease. Neurosci Lett 2007;423:82–7
   PubMedGoogle Scholar
• Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, et al. Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci USA 2008;105:8754–9
   PubMedGoogle Scholar
• Liu R-M, Van Groen T, Katre A, Cao D, Kadisha I, Ballinger C, Wang L, et al. Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer’s disease. Neurobiol Aging 2011;32:1079–89
   PubMedGoogle Scholar
• Kranenburg O, Bouma B, Gent YYJ, Aarsman CJ, Kayed R, Posthuma G, Schiks B, et al. β-Amyloid (Aβ) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation. Mol Cell Neurosci 2005;28:496–508
   PubMedGoogle Scholar
• Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-β (Aβ) degradation and inhibits Aβ-induced neurodegeneration. J Neurosci 2003;23:8867–71
   PubMed Web of Science ®Google Scholar
• Cacquevel M, Launay S, Castel H, Benchenane K, Chéenne S, Buée L, Moons L, et al. Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms. Neurobiol Dis 2007;27:164–73
   PubMedGoogle Scholar
• Fabbro S, Seeds NW. Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. J Neurochem 2009;109:303–15
   PubMedGoogle Scholar
• Medina MG, Ledesma MD, Domínguez JE, Medina M, Zafra D, Alameda F, Dotti CG, et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J 2005;24:1706–16
   PubMedGoogle Scholar
• Radcliffe R, Heinze T. Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: a possible additional role for plasminogen activator? Arch Biochem Biophys 1981;211:750–61
   PubMedGoogle Scholar
• Machovich R, Owen WG. Denatured proteins as cofactors for plasminogen activation. Arch Biochem Biophys 1997;344:343–9
   PubMed Web of Science ®Google Scholar
• Galántai R, Módos K, Fidy J, Kolev K, Machovich R. Structural basis of the cofactor function of denatured albumin in plasminogen activation by tissue-type plasminogen activator. Biochem Biophys Res Commun 2006;341:736–41
   PubMedGoogle Scholar
• Zonneveld AJ van, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. J Biol Chem 1986;261:14214–8
   PubMedGoogle Scholar
• Stein PL, Zonneveld AJ van, Pannekoek H, Strickland S. Structural domains of human tissue-type plasminogen activator that confer stimulation by heparin. J Biol Chem 1989;264:15441–4
   PubMedGoogle Scholar
• Maas C, Schiks B, Strangi RD, Hackeng TM, Bouma BN, Gebbink MFBG, Bouma B. Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs. Amyloid 2008;15:166–80
   PubMed Web of Science ®Google Scholar
• Zonneveld AJ van, Veerman H, Pannekoek H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci USA 1986;83:4670–4
   PubMedGoogle Scholar
• Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. A structural model for Alzheimer’s β-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 2002;99:16742–7
   PubMed Web of Science ®Google Scholar
• Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, Riek R. 3D structure of Alzheimer’s amyloid-β(1–42) fibrils. Proc Natl Acad Sci USA 2005;102:17342–7
   PubMed Web of Science ®Google Scholar
• Wiltzius JJW, Sievers SA, Sawaya MR, Cascio D, Popov D, Riekel C, Eisenberg D. Atomic structure of the cross-β spine of islet amyloid polypeptide (amylin). Protein Sci 2008;17:1467–74
   PubMedGoogle Scholar
• Haupt C, Morgado I, Kumar ST, Parthier C, Bereza M, Hortschansky P, Stubbs MT, et al. Amyloid fibril recognition with the conformational B10 antibody fragment depends on electrostatic interactions. J Mol Biol 2011;405:341–8
   PubMed Web of Science ®Google Scholar
• Haupt C, Bereza M, Kumar ST, Kieninger B, Morgado I, Hortschansky P, Fritz G, et al. Pattern recognition with a fibril-specific antibody fragment reveals the surface variability of natural amyloid fibrils. J Mol Biol 2011;408:529–40
   PubMed Web of Science ®Google Scholar
• Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, Näslund J, Richards G, et al. Endogenous proteins controlling amyloid β-peptide polymerization possible implications for β-amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem 1999;274:15990–5
   PubMed Web of Science ®Google Scholar
• Yang S-P, Bae D-G, Kang HJ, Gwag BJ, Gho YS, Chae C-B. Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer’s disease. Neurobiol Aging 2004;25:283–90
   PubMed Web of Science ®Google Scholar
• Rutgers KS, Van Remoortere A, Van Buchem MA, Verrips CT, Greenberg SM, Bacskai BJ, Frosch MP, et al. Differential recognition of vascular and parenchymal beta amyloid deposition. Neurobiol Aging 2011;32:1774–83
   PubMed Web of Science ®Google Scholar
• Verheijen JH, Caspers MP, Chang GT, De Munk GA, Pouwels PH, Enger-Valk BE. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986;5:3525–30
   PubMed Web of Science ®Google Scholar
• Gething MJ, Adler B, Boose JA, Gerard RD, Madison EL, McGookey D, Meidell RS, et al. Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain. EMBO J 1988;7:2731–40
   PubMedGoogle Scholar
• Bennett WF, Paoni NF, Keyt BA, Botstein D, Jones AJ, Presta L, Wurm FM, et al. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 1991;266:5191–201
   PubMed Web of Science ®Google Scholar
• Citarella F, Ravon DM, Pascucci B, Felici A, Fantoni A, Hack CE. Structure/function analysis of human factor XII using recombinant deletion mutants. Eur J Biochem 1996;238:240–9
   PubMedGoogle Scholar